Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?, World Journal of Surgery, vol.90, issue.5, p.8728, 2006. ,
DOI : 10.1007/s00268-005-0329-x
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma, Cancer, vol.356, issue.2, p.24350, 2009. ,
DOI : 10.1002/cncr.24030
The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation, Eur J Cancer Oxf Engl mars, vol.46, issue.4, p.7139, 1990. ,
Update in Adrenocortical Carcinoma, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.12, p.455164, 2013. ,
DOI : 10.1210/jc.2013-3020
Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment, Frontiers in Cell and Developmental Biology, vol.3, p.45, 2015. ,
DOI : 10.3389/fcell.2015.00045
Diagnosis, treatment and outcome of adrenocortical cancer, British Journal of Surgery, vol.6, issue.4, p.291306, 2015. ,
DOI : 10.1002/bjs.9743
Prognostic factors in stage III???IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study, Annals of Oncology, vol.26, issue.10, p.211925, 2015. ,
DOI : 10.1093/annonc/mdv329
The next generation of therapies for adrenocortical cancers, Trends in Endocrinology & Metabolism, vol.23, issue.7, p.34350, 2012. ,
DOI : 10.1016/j.tem.2012.04.001
The molecular basis of adrenocortical cancer, Cancer Genetics, vol.205, issue.4, p.1317, 2012. ,
DOI : 10.1016/j.cancergen.2012.02.009
Transcriptome analysis of adrenocortical cancers (ACC): from molecular classification to the identification of new treatments, Endocrine Related Cancer, vol.18, issue.2, p.1527, 2011. ,
DOI : 10.1530/ERC-10-0220
Current and emerging therapeutic 36 ,
The 'omics' of adrenocortical tumours for personalized medicine, Nature Reviews Endocrinology, vol.20, issue.4, p.21528, 2014. ,
DOI : 10.1038/nrendo.2013.272
Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors, Cancer Res. 15 sept, vol.61, issue.18, p.67627, 2001. ,
Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling, Clinical Cancer Research, vol.15, issue.2, p.66876, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1067
Integrated genomic characterization of adrenocortical carcinoma, Nature Genetics, vol.11, issue.6, p.60712, 2014. ,
DOI : 10.1038/ng.2953
Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.10, p.40808, 2013. ,
DOI : 10.1210/jc.2013-2165
Novel Insights into the Genetics and Pathophysiology of Adrenocortical Tumors, Frontiers in Endocrinology, vol.8, p.96, 2015. ,
DOI : 10.1371/journal.pone.0080725
URL : https://hal.archives-ouvertes.fr/inserm-01247515
Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers ,
MicroRNA Era: The Importance for Diagnosis and Prognosis of Adrenocortical Tumors, BioMed Research International, vol.94, issue.3, p.381917, 2014. ,
DOI : 10.1158/0008-5472.CAN-10-2014
MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations, Human Pathology, vol.45, issue.8, p.155562, 2014. ,
DOI : 10.1016/j.humpath.2014.04.005
MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy, Cellular and Molecular Life Sciences, vol.71, issue.5, p.41728, 2015. ,
DOI : 10.1007/s00018-014-1752-7
The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma, Endocrine Related Cancer, vol.18, issue.6, p.64355, 2011. ,
DOI : 10.1530/ERC-11-0082
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy, Cancer, vol.70, issue.8, p.16309, 2011. ,
DOI : 10.1002/cncr.25724
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer, Clinical Cancer Research, vol.15, issue.24, p.768492, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1587
Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers, Histopathology, vol.56, issue.4, p.56776, 2014. ,
DOI : 10.1111/his.12283
Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients, Endocrine Related Cancer, vol.20, issue.4, p.57994, 2013. ,
DOI : 10.1530/ERC-13-0051
MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors, Surgery, vol.154, issue.6, p.12248, 2013. ,
DOI : 10.1016/j.surg.2013.06.022
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874721
Analysis of circulating microRNAs in adrenocortical tumors, Laboratory Investigation, vol.28, issue.3, p.3319, 2014. ,
DOI : 10.1016/S0002-9440(10)63846-1
Dysregulation of microRNAs in adrenocortical tumors, Molecular and Cellular Endocrinology, vol.351, issue.1, p.11828, 2012. ,
DOI : 10.1016/j.mce.2011.09.041
URL : https://hal.archives-ouvertes.fr/hal-00728034
MicroRNAs in cancer treatment and prognosis, Am J Cancer Res, vol.2, issue.4, p.41433, 2012. ,
Refining microRNA target predictions: Sorting the wheat from the chaff, Biochemical and Biophysical Research Communications, vol.445, issue.4, p.7804, 2014. ,
DOI : 10.1016/j.bbrc.2014.01.181
Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival, Journal of Clinical Oncology, vol.27, issue.7, p.110815, 2009. ,
DOI : 10.1200/JCO.2008.18.5678
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4, Nature, vol.244, issue.5259, p.6805, 1970. ,
DOI : 10.1038/227680a0
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications., Proceedings of the National Academy of Sciences, vol.76, issue.9, p.43504, 1979. ,
DOI : 10.1073/pnas.76.9.4350
Combination Chemotherapy in Advanced Adrenocortical Carcinoma, New England Journal of Medicine, vol.366, issue.23, p.218997, 2012. ,
DOI : 10.1056/NEJMoa1200966
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study, The Lancet Oncology, vol.16, issue.4, p.42635, 2015. ,
DOI : 10.1016/S1470-2045(15)70081-1
: a Myc-repressed gene involved in cancer and cell stress, Acta Biochimica et Biophysica Sinica, vol.40, issue.7, p.62535, 2008. ,
DOI : 10.1111/j.1745-7270.2008.00434.x
The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications, The FASEB Journal, vol.24, issue.11, p.415366, 2010. ,
DOI : 10.1096/fj.09-151464
Crystal Structure of the Human N-Myc Downstream-regulated Gene 2 Protein Provides Insight into Its Role as a Tumor Suppressor, Journal of Biological Chemistry, vol.286, issue.14, p.1245060, 2011. ,
DOI : 10.1074/jbc.M110.170803
NDRG2 expression and mutation in human liver and pancreatic cancers, World Journal of Gastroenterology, vol.10, issue.23, p.351821, 2004. ,
DOI : 10.3748/wjg.v10.i23.3518
Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma, Int J Cancer J Int Cancer. 1 nov, vol.123, issue.9, p.20806, 2008. ,
Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer, BMC Cancer, vol.39, issue.2, p.303, 2008. ,
DOI : 10.1038/emm.2007.77
NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma, Carcinogenesis. avr, vol.30, issue.4, p.598605, 2009. ,
Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer, BMC Cancer, vol.124, issue.1, p.14, 2011. ,
DOI : 10.1002/ijc.23945
Low expression of N-myc downstream-regulated gene 2 in oesophageal squamous cell carcinoma correlates with a poor prognosis, BMC Cancer, vol.385, issue.1, p.305, 2013. ,
DOI : 10.1016/j.bbrc.2009.05.038
Expression of NDRG2 in human lung cancer and its correlation with prognosis, Medical Oncology, vol.10, issue.23, p.421, 2013. ,
DOI : 10.1007/s12032-012-0421-7
NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-?? production, Carcinogenesis, vol.33, issue.10, p.18828, 2012. ,
DOI : 10.1093/carcin/bgs211
Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer, Biochemical and Biophysical Research Communications, vol.441, issue.1 ,
DOI : 10.1016/j.bbrc.2013.10.010
8 nov 2013, p.1027 ,
NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients, Oncotarget, vol.6, issue.10, p.758496, 2015. ,
DOI : 10.18632/oncotarget.3170
NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells, Oncotarget, vol.6, issue.19, p.17594604, 2015. ,
DOI : 10.18632/oncotarget.4009
NDRG3 and NDRG4, two novel tumor-related genes, Biomedicine & Pharmacotherapy, vol.67, issue.7, p.6814, 2013. ,
DOI : 10.1016/j.biopha.2013.04.009
Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines, Biochemical and Biophysical Research Communications, vol.358, issue.1, p.1649, 2007. ,
DOI : 10.1016/j.bbrc.2007.04.089
Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.1, p.17484, 2013. ,
DOI : 10.1210/jc.2012-2993
DNA Methylation of NDRG2 in Gastric Cancer and Its Clinical Significance, Digestive Diseases and Sciences, vol.27, issue.3, p.71523, 2013. ,
DOI : 10.1007/s10620-012-2393-z
miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3, Oncol Rep. nov, vol.26, issue.5, p.12816, 2011. ,
Down-regulation of NDRG2 gene expression in human colorectal cancer involves promoter methylation and microRNA-650, Biochemical and Biophysical Research Communications, vol.406, issue.4, p.5348, 2011. ,
DOI : 10.1016/j.bbrc.2011.02.081
miR-483-5p Promotes Invasion and Metastasis of Lung Adenocarcinoma by Targeting RhoGDI1 and ALCAM, Cancer Research, vol.74, issue.11, p.303142, 2014. ,
DOI : 10.1158/0008-5472.CAN-13-2193
miR-139-5p is a regulator of metastatic pathways in breast cancer, RNA, vol.19, issue.12, p.176780, 2013. ,
DOI : 10.1261/rna.042143.113
Delivering the promise of miRNA cancer therapeutics, Drug Discovery Today, vol.18, issue.5-6, pp.5-62829, 2013. ,
DOI : 10.1016/j.drudis.2012.10.002
Interplay between microRNAs and WNT/??-catenin signalling pathway regulates epithelial???mesenchymal transition in cancer, European Journal of Cancer, vol.51, issue.12, p.163849, 1990. ,
DOI : 10.1016/j.ejca.2015.04.021
N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial???mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling, Cancer Letters, vol.354, issue.1, p.3342, 2014. ,
DOI : 10.1016/j.canlet.2014.06.023
The Effects of NDRG2 Overexpression on Cell Proliferation and Invasiveness of SW48 Colorectal Cancer Cell Line, Iran J Med Sci. sept, vol.40, issue.5, p.4309, 2015. ,
Loss of NDRG2 promotes epithelialmesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression, J Hepatol. 17 août, 2015. ,
Overexpression of N-Myc Downstream-Regulated Gene 2 (NDRG2) Regulates the Proliferation and Invasion of Bladder Cancer Cells In Vitro and In Vivo, PLoS ONE, vol.30, issue.10, p.76689, 2013. ,
DOI : 10.1371/journal.pone.0076689.t003